Biomarkers In Seizure To Predict Recurrence and Severe Outcomes
NCT ID: NCT01774500
Last Updated: 2014-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2013-01-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Diagnostic Belief Updating Study to verIfy the Utility of BioEP in First Seizure Clinics.
NCT05764252
Severity: Quantifying the Severity of Generalized Tonic-clonic Seizures (GTCS) With Connected Devices
NCT05477121
Assessment of Severity and Prognosis for Patients With Status Epileptics(SE)
NCT02269137
A Retrospective Study to Validate BioEP as an Assessment Aid for Seizure Susceptibility
NCT06669364
Prognosis Factors Associated With Convulsive Status Epilepticus in Adults
NCT00318578
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion criteria :
* seizure within 24h of attendance to an Emergency department (ED)
* or seizure in the ED
Exclusion Criterie :
* pregnancy
* prisoneer
Primary endpoint :
\- recurrence of seizure, hospitalisation more than 24 hours or death within seven days
Secondary endpoint :
* Hospital free days at day 7 and day 28
* Death, ICU admission, or neurosurgical intervention at day 7 and day 28
* Return visit to the ED or re admission at day 7 and day 28
data collection:
* demographics
* past medical history, medication
* vital signs (Heart rate, temperature, Pulse oxymetry, blood pressure, GCS) on arrival
* Pathology (White cell count, Sodium, Calcium, Glucose, lactate)
* Protein S100B and Copeptin
* Seizure characteristics (Witnessed, simple, partial, complex, provoked, acute symptomatic, idiopathic)
* Discharge plan, outcomes
Follow up at day 7 and day 28, hospital visit or phone call
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Or Seizure in the ED
Exclusion Criteria
* Prisoner
* age \< 18 years old
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Groupe Hospitalier Pitie-Salpetriere
OTHER
Barts & The London NHS Trust
OTHER
Bistro Study Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yonathan Freund
Chef de Clinique - Research fellow. MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Lariboisiere
Paris, , France
Groupe Hospitalier pitie-salpetriere
Paris, , France
Hopital Tenon
Paris, , France
Royal London Hospital, Barts Health NHS Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BISTRO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.